Effect of body mass index on the outcome of children with acute myeloid leukemia

Cancer

Volumn 118, Issue 23, 2012, Pages 5989-5996

  Inaba, Hiroto ^a,b   Surprise, Harriet C ^a   Pounds, Stanley ^a   Cao, Xueyuan ^a   Howard, Scott C ^a,b   Ringwald Smith, Karen ^a   Buaboonnam, Jassada ^a   Dahl, Gary ^c   Bowman, W Paul ^d   Taub, Jeffrey W ^e   Campana, Dario ^f   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b   Rubnitz, Jeffrey E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d Stanford Cancer Center ^*  (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

acute myeloid leukemia; body mass index; children; survival; toxicity

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE;

EID: 84869505084     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27640     Document Type: Article

References (28)

1. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27: 4007-4013.
2. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
3. Grimwade D, Hills RK,. Independent prognostic factors for AML outcome [serial online]. Hematol Am Soc Hematol Educ Program. 2009: 385-395.
4. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005; 293: 203-211. (Pubitemid 40095871)
5. Arnaout MK, Radomski KM, Srivastava DK, et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia. 2000; 14: 1736-1742.
6. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001; 19: 2804-2811. (Pubitemid 32538188)
7. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009; 23: 1410-1416.
8. Kruskal WH, Wallis WA,. Use of ranks in 1-criterion variance analysis. J Am Stat Assoc. 1952; 47: 583-621.
9. Kaplan EL, Meier P,. Non-parametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35: 1-39. (Pubitemid 8018922)
11. Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
12. Cox D,. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187-220.
13. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
14. Gray RJ,. Spline-based tests in survival analysis. Biometrics. 1994; 50: 640-652. (Pubitemid 24320813)
15. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007; 25: 2063-2069. (Pubitemid 46972792)
16. Hijiya N, Panetta JC, Zhou Y, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006; 108: 3997-4002. (Pubitemid 44913268)
17. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR,. Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia [published online ahead of print February 7, 1012]. Haematologica. 2012.
18. Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol. 2012; 91: 359-365.
19. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M,. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997; 11: 1661-1664. (Pubitemid 27458604)
20. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012; 119: 49-54.
21. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM,. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010; 303: 242-249.
22. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ,. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005; 45: 881-891. (Pubitemid 41552155)
23. Tilg H, Moschen AR,. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783. (Pubitemid 44453463)
24. Wiernik PH, Serpick AA,. Factors effecting remission and survival in adult acute nonlymphocytic leukemia (ANLL). Medicine (Baltimore). 1970; 49: 505-513.
25. de Onis M, Blossner M, Borghi E, Frongillo EA, Morris R,. Estimates of global prevalence of childhood underweight in 1990 and 2015. JAMA. 2004; 291: 2600-2606. (Pubitemid 38702778)
26. Chandra RK,. Nutrition and the immune system from birth to old age. Eur J Clin Nutr. 2002; 56 (suppl 3): S73-S76.
27. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG,. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group Study CCG-2891. J Clin Oncol. 2000; 18: 1845-1855. (Pubitemid 30261922)
28. Rodvold KA, Rushing DA, Tewksbury DA,. Doxorubicin clearance in the obese. J Clin Oncol. 1988; 6: 1321-1327.